EGFR and hepatocellular carcinoma: The multi-kinase inhibitor sorafenib and the receptor tyrosine kinase inhibitor lenvatinib are currently being used as first-line treatments against HCC (134) and blocking EGFR has shown to further increase the efficacy of those two drugs (135, 136).